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Abstract 
 
 In previous studies have been reported a controversy between the reactivity 
of mono and polyclonal antibodies in different cells populations of the mouse. In 
this study we focus on the immunoreactivity of the monoclonal antibody VEGF (C-
1) in order to analyze its expression in two cell populations of regenerating mouse 
liver (hepatocytes and endothelial cells) after partial hepatectomy, and two 
transplanted hepatocarcinomas (ES2 and SS1K). C3H/S male mice were divided 
into two groups and kept under standard conditions for circadian periodicity 
analysis, one group were transplanted with the tumors into the subcutaneous tissue 
of the animal flank and the other group were subjected to a partial hepatectomy (70 
%). The animals were killed by decapitation and exsanguination. Samples of 
regeneration liver, ES2 and SS1K tumors were processed for histology and 
immunostained with VEGF (C-1) mouse monoclonal IgG2a antibody. The results 
showed strongly immunopositivity reaction for VEGF either in hepatocytes or 
endothelial cells of mouse regenerating liver. We also demonstrated positive 
immunoreaction in both malignant tumors ES2 and SS1K endothelial and 
parenchymal cells. We conclude that the use of VEGF (C-1) mouse monoclonal 
IgG2a antibody can be applied successfully in experimental design leading to study 
processes involved in mice’s angiogenesis. 
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Introduction 
 
everal growth factors have been described with angiogenic activity (Ferrara and Davis-
Smyth, 1997; Plate et al., 1992) but vascular endothelial growth factor (VEGF) is the 
most potent and specific for both angiogenesis and vasculogenesis (Mustonen and Alitalo, 1995; 
Shibuya, 1995). 
S 
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In regenerating liver, after partial hepatectomy, both hepatocytes and nonparenchymal cells 
express VEGF mRNA (Mochida et al., 1996), suggesting that VEGF plays a significant role in rat 
liver regeneration (Shimizu et al., 2001; Taniguchi et al., 2001). However, this situation has not 
been examined in detail in mouse. 
In addition to the crucial role in physiological angiogenesis, VEGF is also a key player in 
pathological neovascularization (Veikkola and Alitalo, 1999). 
The onset of angiogenesis is believed to be an early event in tumorigenesis and may 
facilitate tumor progression and metastasis (Folkman et al., 1989). It has been speculated that 
VEGF may function as a tumor angiogenesis factor in vivo because the expression pattern of VEGF 
is consistent with a role in embryonic angiogenesis (Breier et al., 1992). 
On the other hand, some authors have studied the reactivity of a broad panel of antibodies 
directed to human antigens, looking for cross-reactivity with mouse epitopes (Martín and Badrán, 
1998). As a result, they found a group of mono and polyclonal antibodies reacting to different cells 
of the mouse, and others that did not (Martín et al., 2001). 
Bearing in mind these results we used the monoclonal antibody VEGF (C-1) in order to 
study its expression in two cell populations of regenerating mouse liver (hepatocytes and 
endothelial cells), and two transplanted, fast growing undifferentiated hepatocarcinomas (ES2 and 
SS1K). 
 
Material and Methods  
 
Animals C3H/S male mice kept under standard conditions for circadian-periodicity analysis, caged 
singly with food and water ad libitum, were used. When they were 90 days old, they were divided 
in two groups. Tumors were transplanted into the subcutaneous tissue of each animal flank of one 
of the groups, while the mice of the other group were subjected to a partial hepatectomy (70 %) at 
10:00 hours. 
 
Tumor grafts For the grafting technique, small pieces of the tumor without necrotic changes were 
trimmed with scissors, suspended in saline (1, 2) and injected (0.2 ml) into the hosts. The whole 
procedure was carried out aseptically. 
 
Tissue samplesThe animals were killed by decapitation and exsanguination. The hepatectomized 
mice were killed 26 hours post hepatectomy, and the tumor bearing ones, ES2 and SS1K tumors 
were removed promptly and fixed in 10 % buffered formalin for 24 h. All tissue samples were 
processed routinely and embebbed in paraffin. Five-micrometer sections were cut, placed on 
positive-charge slides, and dried at 58ºC overnight.  
   
Immunohistochemistry 
 
Sections were deparaffinized in xylene, rehydrated through graded alcohols and washed in 
Tris buffer saline (TBS) pH 7.4. After blocking endogenous peroxidase with 3% H2O2 for 15 
minutes, heat-induced epitope retrieval (HIER) was used (Shi et al., 1991; Cattoretti et al., 1993). 
Briefly, slides were washed in TBS and placed in a microwavable platic container filled with 250 
ml of 0.01 M of citrate buffer pH 6 and irradiated in a household microwave oven, with a rotating 
carousel, at 750 W for 10 minutes (2 cycles of 5 minutes). Distilled water was used to refilled the 
container after each cycle to maintain the buffer concentration. 
After microwaving the slides were allowed to cool in the solution for 20 minutes (Battifora 
et al., 1995), then washed in TBS an incubated with primary antibody VEGF (C-1) mouse 
monoclonal IgG2a antibody (Santa Cruz Biotechnology, California, USA) at 1/40 dilution in a 
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humid chamber during 1 hour at room temperature. As detection system Envision (Dako, 
Carpinteria, California, USA) was used. The reaction was developed using 3’3-diaminobenzidine 
(Sigma) in TBS with 0.03 % H2O2. The sections were slightly counterstained with Mayer’s 
Hematoxylin and mounted. Negative controls were run in parallel, omitting primary antibody.  
 
Results 
 
The results showed strongly immunopositivity reaction with intracytoplasmic localization 
for VEGF in hepatocytes (Figure 1) as well as in the sinusoid endothelial cells (Figure 2) of mouse 
regeneration liver.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Hepatocytes of regenerating liver showing VEGF (C-1) reactivity (40X). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Endothelial cells of regenerating liver showing positive reaction to VEGF (C-1) (40X). 
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We also demonstrated positive immunoreaction in both malignant tumor ES2 (Figure 3) and 
SS1K (Figure 4). In both tumors we can see a positive reaction in parenchymal and endothelial 
cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: ES2 malignant tumor. Endothelial and  parenchymal cells positive to VEGF (C-1) (40X). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: SS1K malignant tumor endothelial and parenchymal cells are positive (40X). 
 
 
Discussion 
 
Previous studies support the concept that VEGF mRNA is formed in some primary tumors, 
VEGF is produced by tumor cells lines in vitro (Breier et al., 1992) and that its mitogenic activity 
appears to be restricted to endothelial cells (Conn et al., 1990). Others authors demonstrated that 
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neoplastic cells are thought to be the main source of VEGF in tumors (Veikkola and Allitalo, 1991). 
Our findings supported the idea that in both transplanted mouse tumors, VEGF expressed itself 
either in endothelial cells or in the parenchymal ones.   
On the other hand, there are many authors that using immunohistochemistry in different 
laboratory species found unreactivity of some of the antibodys tested. This would be explained by 
differences in the epitope structure among species as has been reported by Zeng et al. (1996). In 
their study of reactivity of antihuman macrophage antibodies in 10 different species, except in 
mouse, they found very variable results according to the animal tested.  
As we want to study the behavior of VEGF in different tissues of the mouse, we used the 
VEGF (C1) which is a mouse monoclonal IgG2a antibody corresponding to aminoacids 1-140 of 
VEGF of human origin. We based the selection of this antibody on our intention to avoid the 
difficulties previously demonstrated by other authors (Zeng et al., 1996, Martín and Badrán, 1998) 
in the selection of the animal specie but with the uncertainty of obtained positive results or not, 
because until now the antibody has been used in rats, but not in mice. However, these positive 
results in C3HS mice may not be generalized to other mice strains because of possible intraspecies 
differences.  
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